SERA
Sera Prognostics, Inc.3.5600
+0.1800+5.33%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
137.40MP/E (TTM)
-Basic EPS (TTM)
-0.76Dividend Yield
0%Recent Filings
8-K
PRIME data published
Sera Prognostics posted a January 2026 investor presentation highlighting full PRIME study publication, showing PreTRM test plus interventions cut NICU admissions 20%, deliveries before 32 weeks 56%, and neonatal morbidity odds 20% in 5,018 patients. Cash of $102.4M as of September 30, 2025, funds commercialization through 2028. PRIME data unlocks pilots. Forward-looking statements carry risks.
8-K
PRIME study validates PreTRM
Sera Prognostics announced publication of the PRIME study results on January 7, 2026, in the Pregnancy Journal, showing its PreTRM blood test plus interventions slashed earliest preterm births by 56% before 32 weeks and 32% before 35 weeks in a 5,018-woman trial. NICU admissions dropped 20%, with one NICU day saved per 4.2 patients screened. PRIME bolsters evidence for low-risk pregnancies. Management discusses at Jefferies chat January 9.
8-K
PRIME study publication accepted
Sera Prognostics announced on November 24, 2025, that findings from its PRIME study—one of the largest on preterm birth—were accepted for publication in a peer-reviewed journal, following an earlier late-breaking abstract presentation at SMFM. The company plans to share full manuscript data at upcoming medical meetings and analyst events. Publication bolsters validation for the PreTRM test. PRIME advances precision pregnancy care.
10-Q
Q3 FY2025 results
Sera Prognostics narrowed Q3 FY2025 operating losses to $9.0M from $8.9M y/y, yet netted $7.8M versus $7.9M last year, thanks to $1.2M other income topping $0.9M. Revenue dipped to $16K from $29K y/y while costs climbed to $41K from $13K; YTD revenue rose 34% to $71K with losses steady at $24.0M. Cash burn hit $19.5M YTD versus $7.9M prior, offset by $53.6M from February equity raise, leaving $102.4M in cash/securities. Leased space shrinks to 20k sf through 2034 with $1.1M buildout aid. PreTRM adoption hinges on payer contracts.
8-K
Q3 revenue dips; cash strong
Sera Prognostics reported Q3 2025 revenue of $16,000, down from $29,000 a year ago, with net loss steady at $7.8 million. Yet cash swelled to $102.4 million, funding operations through 2028. Launched first Nevada Medicaid pilot; hired CMO Tiffany Inglis and Head of Commercial Ops Marisol Urbano. Payer talks span 13 states.
AWHL
Aspira Women's Health Inc.
0.36+0.00
BMRA
Biomerica, Inc.
2.37-0.08
CODX
Co-Diagnostics, Inc.
0.25-0.02
NTRA
Natera, Inc.
227.40-1.00
PFSA
Profusa, Inc.
0.11-0.01
SENS
Senseonics Holdings, Inc.
6.62-0.17
SHC
Sotera Health Company
16.70-0.10
SMLR
Semler Scientific, Inc.
17.40+1.37
SRDX
Surmodics, Inc.
42.98+0.00
UTMD
Utah Medical Products, Inc.
58.43+0.94